Pepaxti for Relapsed/refractory multiple myeloma
Quick answer: Pepaxti is used for Relapsed/refractory multiple myeloma as part of a alkylating peptide-drug conjugate (melphalan flufenamide) treatment regimen. Peptide-conjugated alkylating agent (melflufen) that releases melphalan intracellularly via aminopeptidase cleavage, causing DNA damage in myeloma cells The specific dosing for Relapsed/refractory multiple myeloma is determined by your prescriber based on individual factors.
Why is Pepaxti used for Relapsed/refractory multiple myeloma?
Pepaxti belongs to the Alkylating peptide-drug conjugate (melphalan flufenamide) class. Peptide-conjugated alkylating agent (melflufen) that releases melphalan intracellularly via aminopeptidase cleavage, causing DNA damage in myeloma cells This action makes it useful for treating or managing Relapsed/refractory multiple myeloma in patients for whom this approach is clinically appropriate.
It is one of several treatment options. Whether Pepaxti is the right choice for a specific patient depends on the type and severity of Relapsed/refractory multiple myeloma, response to previous treatments, individual risk factors, and clinical guidelines.
Typical dosing for Relapsed/refractory multiple myeloma
Common adult dosing range: 40 mg IV on day 1 of each 28-day cycle, with dexamethasone. The actual dose for Relapsed/refractory multiple myeloma depends on:
- Severity of the condition
- Patient's age, weight, and organ function
- Other medications being taken
- Treatment response and tolerability
For complete dosing details, see the Pepaxti medicine page.
What to expect
Pepaxti treatment for Relapsed/refractory multiple myeloma typically involves:
- Onset of effect: varies by indication and dose — some effects are immediate, others take days to weeks
- Treatment duration: some courses are short-term, others are long-term or lifelong depending on Relapsed/refractory multiple myeloma
- Monitoring: follow-up visits to assess response and adjust dosing
- Side-effect awareness: learning what to expect and what warrants medical attention
Alternatives to consider
If Pepaxti is not appropriate or not tolerated, alternatives within the same class or different therapeutic classes may be considered. See all Alkylating peptide-drug conjugate (melphalan flufenamide) for related options.
When to talk to your doctor
Discuss with your prescriber if you experience:
- Inadequate symptom control on Pepaxti
- Side effects affecting daily life
- New medications or supplements that may interact
- Pregnancy planning or pregnancy
- Major changes in health status
Related information
Pepaxti full prescribing information · All Alkylating peptide-drug conjugate (melphalan flufenamide) alternatives
Frequently asked questions
How effective is Pepaxti for Relapsed/refractory multiple myeloma?
Effectiveness varies by individual response, dose, and severity. Pepaxti is one of several treatment options for Relapsed/refractory multiple myeloma, supported by clinical evidence within the alkylating peptide-drug conjugate (melphalan flufenamide) class. Discuss expected response with your prescriber.
How long do I need to take Pepaxti for Relapsed/refractory multiple myeloma?
Treatment duration depends on the nature of Relapsed/refractory multiple myeloma — some treatments are short-term, others long-term or lifelong. Never stop on your own; discontinuation requires clinical guidance to avoid relapse or rebound effects.
What are the main side effects of Pepaxti when used for Relapsed/refractory multiple myeloma?
Common and serious side effects are class-related and substance-specific. See the full medicine page for the complete profile. Report any unexpected effects to your prescriber.
Are there alternatives to Pepaxti for Relapsed/refractory multiple myeloma?
Yes. Multiple medicines and non-drug options exist for Relapsed/refractory multiple myeloma. Alternatives within the alkylating peptide-drug conjugate (melphalan flufenamide) class share mechanisms; other classes may offer different approaches. Discuss with your clinician.
Last reviewed: by iMedic Medical Editorial Team. Our editorial process.